Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016: 14 Companies & 19 Drug Molecules - Research and Markets

Research and Markets
Posted on: 18 Oct 16

Research and Markets has announced the addition of the "Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016" report to their offering.

Neuromyelitis Optica (Devic's Syndrome) - Neuromyelitis Optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person's immune system (the body's natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

Neuromyelitis Optica (Devic's Syndrome) pipeline therapeutics constitutes close to 19 molecules, out of which approximately 17 molecules are developed by Companies and the remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 4, 2 and 7, respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Neuromyelitis Optica (Devic's Syndrome) Overview
  3. Therapeutics Development
  4. Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Overview
  5. Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis
  6. Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Development by Companies
  7. Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Investigation by Universities/Institutes
  8. Neuromyelitis Optica (Devic's Syndrome) Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Neuromyelitis Optica (Devic's Syndrome) - Products under Development by Companies
  13. Neuromyelitis Optica (Devic's Syndrome) - Products under Investigation by Universities/Institutes
  14. Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development
  • Acorda Therapeutics Inc.
  • Alexion Pharmaceuticals Inc.
  • Biogen Inc.
  • Bionure Farma S.L.
  • Chugai Pharmaceutical Co. Ltd.
  • Clene Nanomedicine Inc.
  • HanAll Biopharma Co. Ltd.
  • Karus Therapeutics Limited
  • LFB S.A.
  • Marathon Pharmaceuticals LLC
  • MedImmune LLC
  • Opexa Therapeutics Inc.
  • Shire Plc
  • Takeda Pharmaceutical Company Limited

For more information about this report visit

View source version on

Business Wire

Last updated on: 18/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.